XENE · Xenon Pharmaceuticals
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $52.29
Note written ·
Price against the kill line
22.6% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $52.29, on record since 11 November 2026. The shares are down 35.1% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $52.29, the 200-day average of adjusted closes as of 11 November 2026, which would show the shares leading the S&P 500; an X-NOVA2 depression topline that meets its primary endpoint without new safety findings would also prove the call wrong.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 9 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 0.0
- Free cash flow, four quarters ($M)
- −357
- Net cash, cash less debt ($M)
- 951
- Free-cash-flow yield (%)
- −9.0
All filed numbers
What Xenon Pharmaceuticals reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) |
|---|---|---|
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| first filed | 0.0 | −100.0 |
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| first filed | 0.0 | — |
| Pre-tax income ($M) | −109 |
| Net income ($M) four quarters: −429 | −110 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +25.9 |
| Operating cash flow ($M) | −356 |
| Capital spending ($M) | 1.0 |
| Free cash flow ($M) | −357 |
| Cash and short-term investments ($M) | 951 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 951 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 1,146 |
| Market value ($M) | 3,979 |
| Enterprise value, market value plus net debt ($M) no debt reported | 3,028 |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 3.5 |
| Free-cash-flow yield (%) | −9.0 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 7.5% of shares outstanding sold short, 4.0 days of average trading to cover, +21.6% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $1.7M | $426K |
| 12 monthsfrom | $1.7M | $22.0M |
The thesis
Xenon Pharmaceuticals' shares are more likely to lag the S&P 500 over the next three months. The epilepsy filing is on track, but a December 2026 depression readout carrying a safety question now decides the near term. Two dated events settle it: the FDA's decision on accepting the azetukalner epilepsy application for review, due about 16 November 2026, and the X-NOVA2 depression topline that Xenon now expects in December 2026.
Xenon's 9 November 2026 third-quarter report brought one change. X-NOVA2 finished enrollment at about 360 patients, and topline data moved up to December 2026 from the first quarter of 2027. Management said on the 9 November 2026 call that the study is powered at 90% to detect a placebo-corrected difference of about 2.5 points on the Hamilton Depression Rating Scale (HAM-D17) at week 6. The readout lands while new psychiatry enrollment remains paused, so a positive result and a safety setback are both live outcomes.
The price already reflects a smaller company. The shares closed at $42.10 on 11 November 2026, down 34.5% over three months from $64.23 on 13 August 2026. That fall followed the 17 September 2026 psychiatry pause, so the market already gives the depression and bipolar programs little value. The rating is Low because the next dated event with the most weight is a binary readout under a safety overhang. Filing acceptance, the likelier near-term positive, is the routine step for an application that has already been submitted.
Bullish and bearish views on Xenon Pharmaceuticals Inc.
The bull case on Xenon Pharmaceuticals Inc. (XENE), in brief: the epilepsy application is under FDA consideration. The bear case: psychiatry safety is unresolved.
Bull case
- The epilepsy application is under FDA consideration. Xenon submitted the focal-seizure New Drug Application (NDA) in September 2026, per its 9 November 2026 results release. Management listed acceptance among milestones expected "over the next few months" on the 9 November 2026 call.
- Cash covers the plan into 2029. Cash, cash equivalents and marketable securities were $1,153.5 million at 30 September 2026, up from $586.0 million at 31 December 2025, with runway into 2029, per the 9 November 2026 release.
- Launch work is under way. On the 9 November 2026 call, CEO Ian Mortimer said the company is "full steam ahead" on launch preparation. He said a specialty pharmacy network is nearing selection and a field payer team is planned for early 2027.
- Executives bought near the October lows. SEC Form 4 filings show Mortimer bought 30,000 shares at $37.38 and CFO Thomas Kelly bought 15,000 shares at $37.32 on 30 September 2026.
- The depression readout comes sooner. Xenon moved X-NOVA2 topline to December 2026 from the first quarter of 2027, per its 9 November 2026 release. A positive result would restore part of the psychiatry value lost after 17 September 2026.
Bear case
- Psychiatry safety is unresolved. New enrollment in the depression and bipolar studies has been paused since September 2026, and the 9 November 2026 release gives no restart date. Chief Medical Officer Chris Kenney said on the 9 November 2026 call that the neuropsychiatric events were "mostly mild or moderate" but were not seen in the Phase 2 X-NOVA study.
- The December readout is smaller than planned. X-NOVA2 closed at about 360 patients against the 450-patient target Xenon gave on 17 September 2026, per the 9 November 2026 release.
- Losses are rising. Third-quarter 2026 net loss was $110.4 million, or $1.11 a share, against $90.9 million a year earlier. Research and development spending rose to $95.6 million from $77.1 million, per the 9 November 2026 release.
- No revenue exists. Xenon reported zero revenue in the first nine months of 2026, against $7.5 million a year earlier, and azetukalner is unapproved.
- A new safety question surfaced in pain. On the 9 November 2026 call, analysts asked about a severe fainting case in a healthy subject in the XEN1701 Phase 1 study. Kenney said he was "not at all convinced" the event was drug-related.
Price setup
The shares closed at $42.10 on 11 November 2026, up from $37.68 on 5 November 2026. They rose through the report, closing at $40.45 on 9 November 2026, $41.39 on 10 November 2026 and $42.10 on 11 November 2026. The 52-week closing low is $33.49 on 16 October 2026, and the 52-week intraday high is $72.66 on 9 July 2026. The last close is 42.1% below that high.
The 50-day average of adjusted closes is $41.91 as of 11 November 2026, and the last close sits just above it. The 200-day average is well above the price, and the shares have not closed above it since the September drop. A move from the $33.49 October low back toward the 200-day average would need a catalyst. FDA acceptance is the closest one, and the December depression data the larger one.
Insider activity is light. Form 4 filings show the 30 September 2026 purchases by the CEO and CFO and a 7,500-share option exercise by the CFO on 15 October 2026. The last open-market sale on file is Kenney's 7,068 shares at an average $60.25 on 28 August 2026, under a Rule 10b5-1 trading plan.
Catalysts ahead
- ~16 November 2026 (est.): FDA 60-day filing decision on the azetukalner focal-seizure NDA submitted in September 2026. Acceptance for review keeps the epilepsy approval path on schedule; a refusal-to-file notice would remove the main pillar of the case.
- 4 December 2026: American Epilepsy Society 2026 Annual Meeting opens in Denver, running to 8 December 2026, with multiple azetukalner presentations. New epilepsy data and the physician reception ahead of launch show how the drug compares with competing epilepsy treatments.
- ~15 December 2026 (est.): X-NOVA2 Phase 3 depression topline, which Xenon expects in December 2026. A clean, positive result would restore psychiatry value lost after the September pause; a miss or new safety signal would confirm an epilepsy-only company.
What would change the view
A daily close above $52.29, the 200-day average of adjusted closes as of 11 November 2026, which would show the shares leading the S&P 500; an X-NOVA2 depression topline that meets its primary endpoint without new safety findings would also prove the call wrong.
What it trades with
Xenon trades on its own regulatory and clinical events more than on any sector group. The September 2026 drop and the November recovery both followed company disclosures. The December 2026 depression readout adds a psychiatry event to the epilepsy calendar, so the shares may react to safety news on either program. The American Epilepsy Society meeting on 4 December to 8 December 2026 is where competing epilepsy data from other companies will also be presented. The $1,153.5 million cash position at 30 September 2026 limits dependence on small-cap biotech funding conditions.
The evidence, claim by claim (6)
- Xenon completed X-NOVA2 depression enrollment at about 360 patients and moved topline data to December 2026 from the first quarter of 2027. Xenon Q3 2026 results release (8-K exhibit 99.1) · as of
- Cash, cash equivalents and marketable securities were $1,153.5 million at 30 September 2026, with runway into 2029. Xenon Q3 2026 results release (8-K exhibit 99.1) · as of
- Q3 2026 net loss was $110.4 million ($1.11 per share) versus $90.9 million; R&D expense was $95.6 million versus $77.1 million. Xenon Q3 2026 10-Q and results release · as of
- The azetukalner focal-seizure NDA was submitted to the FDA in September 2026; no acceptance had been announced as of the Q3 report. Xenon Q3 2026 results release; 9 November 2026 earnings call · as of
- X-NOVA2 is powered at 90% to detect a roughly 2.5-point placebo-corrected HAM-D17 difference at week 6. Xenon Q3 2026 earnings call · as of
- CEO Ian Mortimer bought 30,000 shares at $37.38 and CFO Thomas Kelly bought 15,000 shares at $37.32 in the open market. SEC Form 4 filings dated 1 October 2026 · as of
Sources
- Xenon Pharmaceuticals Inc. - Form 8-K - FY2026 · sec.gov ·
- Xenon (XENE) Q3 2026 Earnings Call Transcript · fool.com ·
- Xenon Pharmaceuticals Inc. - Form 10-Q - FY2026 · sec.gov
- Xenon Reports Third-Quarter 2026 Results and Business Update · tipranks.com
- Xenon announces azetukalner NDA submission to FDA for focal seizures and provides update on psychiatry clinical program · finviz.com
Related · shared themes
ZVRA
Zevra Therapeutics
Zevra Therapeutics is modestly more likely to beat the S&P 500 over three months: MIPLYFFA sold $34.0 million in the third quarter of 2026…
KOD
Kodiak Sciences
Kodiak Sciences' shares look more likely to lag the S&P 500 after a 161.8% three-month run that prices in the DAYBREAK win while share…
ABVX
Abivax SA
Abivax's shares are modestly more likely to beat the S&P 500 over three months because the company guides its US obefazimod ulcerative…
BHVN
Biohaven
Biohaven Ltd. is modestly more likely than not to beat the S&P 500 over three months: the SK Biopharmaceuticals licence has cleared US…